Simris Alg AB (publ) Total Liabilities
Simris Alg AB (publ) total liabilities. Based on the latest financial reports, Simris Alg AB (publ) (SIMRIS-B) has total liabilities worth Skr136.97 Million SEK (≈ $14.74 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See SIMRIS-B defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Simris Alg AB (publ) (2012–2025)
Total liabilities of Simris Alg AB (publ) from 2012 to 2025. This chart illustrates how Simris Alg AB (publ)'s total liabilities have evolved over time, based on quarterly financial data.
Simris Alg AB (publ) Competitors by Total Liabilities
The table below lists competitors of Simris Alg AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Theta Edge Bhd
KLSE:9075
|
Malaysia | RM43.41 Million |
|
Hawthorn Resources Ltd
AU:HAW
|
Australia | AU$1.59 Million |
|
Pinehill Pacific Bhd
KLSE:1902
|
Malaysia | RM-7.95 Million |
|
Korea SPAC 2
KQ:206400
|
Korea | ₩5.85 Billion |
|
Big Digital Energy, Inc.
NASDAQ:BGDE
|
USA | $60.56 Million |
|
Calgro M3 Holdings Ltd
JSE:CGR
|
South Africa | ZAC1.96 Billion |
|
Nexen Tire Prf 1
KO:002355
|
Korea | ₩2.95 Trillion |
Liability Composition Analysis (2012–2025)
This chart breaks down Simris Alg AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Simris Alg AB (publ) total assets.
Liquidity & Leverage Metrics
Simris Alg AB (publ) Total Liabilities Ratios Explained
Simris Alg AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 178.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Simris Alg AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Simris Alg AB (publ) (2012–2025)
The table below shows the annual total liabilities of Simris Alg AB (publ) from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr148.85 Million ≈ $16.02 Million |
-1.69% |
| 2024-12-31 | Skr151.42 Million ≈ $16.29 Million |
+1.66% |
| 2023-12-31 | Skr148.94 Million ≈ $16.03 Million |
-8.45% |
| 2022-12-31 | Skr162.68 Million ≈ $17.51 Million |
+1381.58% |
| 2021-12-31 | Skr10.98 Million ≈ $1.18 Million |
+13.88% |
| 2020-12-31 | Skr9.64 Million ≈ $1.04 Million |
-43.98% |
| 2019-12-31 | Skr17.21 Million ≈ $1.85 Million |
+71.18% |
| 2018-12-31 | Skr10.05 Million ≈ $1.08 Million |
-14.11% |
| 2017-12-31 | Skr11.71 Million ≈ $1.26 Million |
+6.13% |
| 2016-12-31 | Skr11.03 Million ≈ $1.19 Million |
-34.90% |
| 2015-12-31 | Skr16.94 Million ≈ $1.82 Million |
+1461.47% |
| 2014-12-31 | Skr1.08 Million ≈ $116.76K |
+54.44% |
| 2013-12-31 | Skr702.52K ≈ $75.60K |
+10.93% |
| 2012-12-31 | Skr633.30K ≈ $68.15K |
-- |
About Simris Alg AB (publ)
Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammen… Read more